Sunday, June 5

7:00-8:00  Breakfast and Registration

8:00-8:15  Welcome and Introduction
Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation
R. Edward Hogan, MD, President, AES
Helen Cross, MD, President, ILAE

SESSION I: IMPACT OF COVID ON CLINICAL TRIALS

Moderator: Kimford Meador, MD

8:15-8:20  Patient/Caregiver Perspective
Kim Nye, TESS Research Foundation

8:20-8:50  Panel Discussion: Is COVID helping or hurting drug development?
R. Edward Hogan, MD
Elaine Wirrell, MD
Kathryn Davis, MD
Lilly Frohlich, MPH
Kim Nye

8:50-9:05  Remote Trial Design - IQVIA
Penny Randall, MD, MBA

9:05-9:30  Q&A

SESSION II: PRECLINICAL PIPELINE

Moderator: TBD

9:30-9:40  BL-001 (drug candidate) / IrisRx platform
Christopher Reyes, Bloom Sciences

9:40-9:50  Name of Talk
9:50-10:00 Preclinical Data Supporting the Efficacy of OV329, A Next-Generation GABA Aminotransferase Inhibitor, Against Seizures
Julia Tsai, PhD, Senior VP of Clinical Development and Medical Affairs, Ovid

10:00-10:15 Networking Break

SESSION III: PERSONALIZED MEDICINE: HOW FAR HAVE WE COME AND WHERE ARE WE GOING?

Moderator: TBD

10:15-10:20 Patient/Caregiver Perspective
Daniel Fischer, SCN1A

10:20-10:35 Specific gene mutation screening in infants; who are we finding and who are we missing?
Mark Fitzgerald, MD, PhD

10:35-10:50 Gene based therapies: Why are they likely to succeed, why are they likely to fail?
Annapurna Poduri, MD, MPH

10:50-11:10 Panel Discussion

SESSION IV: PIPELINE FOR GENE BASED THERAPIES

Moderator: TBD

11:10-11:20 Behind the seizures program
Invitae

11:20-11:30 NRTX-1001 (formerly NTX-101) inhibitory neuron cell therapy for drug-resistant temporal lobe epilepsy
Cory Nicholas, Neurona Therapeutics

11:30-11:40 STK-001
Kimberly Parkerson, Stoke Therapeutics

11:40-11:50 NEUmiRNA Therapeutics: Aspiring to cure epilepsy
Henrik Klitgaard, NEUmiRNA Therapeutics

11:50-12:00 CODA Chemogenetic Receptor/Activator Drug
Susan Catalano, CODA Biotherapeutics, Inc.
12:00-12:10  Newly anticipated ASO therapeutic for a genetic target
            Viet Nguyen, Biogen

12:10-1:20  Networking Lunch (lunch on your own)

SESSION V: DIGITAL/DEVICE

Moderator:  Robert Fisher, MD

1:20-1:30  Focused Ultrasound Foundation is an image guided, noninvasive, non-ionizing therapeutic technology
            Vibhor Krishna, Focused Ultrasound

1:30-1:40  EmbracePlus
            Matteo Lai, Empatica

1:40-1:50  Epiminder
            Mark Cook, Cerebral Therapeutics

1:50-2:00  Seer - Long-Term At-Home Epilepsy Monitoring
            Dean Freestone, Seer Medical

2:00-2:10  Epihunter Absence
            Dirk Loeckx, Epihunter

2:10-2:20  Epilog wearable EEG sensor and REMI - remote EEG monitoring platform
            Mark Lehmkuhle, Epitel

2:20-2:30  24/7 EEG SubQ from UNEEG medical
            Lykke Blaabjerg, UNEEG Medical

2:30-2:40  SeizeIT2 project
            Lauren Swinnen, KU Leuven

2:40-2:50  EpiCare@Home
            Benjamin Vandendriessche, Byteflies

2:50-3:10  Networking Break

3:10-5:00 SHARK TANK COMPETITION

3:10-3:15  2021 Community Prize Winner Update: An Epilepsy Self-Management and Resilience Technical App (SMART) for Adolescents & their Community
            Deborah Koltai, PhD

3:15-3:20  2021 Investment Award Winner Update: Generalized Tonic-Clonic Seizure Detection with Video and Radar
            Tobias Loddenkemper, MD
Moderator / Emcee: Tom Stanton

Sharks:

Noah Richmond

Brandy Fureman, PhD, Chief Outcomes Officer, Epilepsy Foundation

David B. Moore, MD

Edward Hogan, MD

Kathryn Davis, MD

3:20  Introduction and Rules

Finalists:  Community Impact Award

An openscience community developing a smart connected patch to detect epilepsy seizures
Clement Le Couedic, AURA Ngo

*EpiPal*: A patient and family-centered software platform for seizure detection, epilepsy safety and management, and treatment insights
Amir Helmy, Epipal

Predictive Seizure Alert App
Serge Lauriou / Helene Blanchard, My Medic Watch

Investment Award

Listen to the brain first, and then map it
Pierre Wijdenes, PhD, Neuraure Biotech, Inc.

Novel therapies for epilepsy prevention
Pavel Klein, PrevEP

Predictive analytics for brain surgery
Max Sims / Brad Mahon, MindTrace Technologies, Inc.

6:00 ACCELERATOR AWARD RECEPTION & AWARD PRESENTATION

2022 MAY LIANG & JAMES LINTOTT SCHOLARSHIP
RECIPIENTS: Wesley Kerr, MD, PhD & Katie Ihnen, MD, PhD

2022 EPILEPSY FOUNDATION LIFETIME ACCELERATOR AWARD

RECIPIENT: Lynn Kramer, MD

Monday, June 6

7:00-8:00 Continental Breakfast and Registration

8:00-8:15 EF Digital Engine
Laura Thrall, CEO, Epilepsy Foundation

SESSION VI: NEW TECHNOLOGY ADOPTION

Moderator: TBD

8:15-8:20 Patient/Caregiver Perspective
Noah Richmond

8:20-8:35 Name of Talk – Care Studio?
Paul Muret, Google

8:35-8:50 Device patient focused design considerations and process
Anouk van Westrhenen

8:50-9:20 Panel Discussion: Obtaining seizure data using remote monitoring/devices

9:20-9:35 Reimbursement: Opportunities and Risks
Jo Ellen Slurzberg

9:35-9:50 Economic models for payers
Ian Duncan

9:50-10:20 Panel Discussion: Reimbursement / Q&A

10:20-10:40 Networking Break

SESSION VII: DEVICES

Moderator: TBD

10:40-10:50 Nile Ai
John Hixson, Nile
SESSION VIII: CREATING EQUITABLE AND INFORMATIVE TRIALS

Moderator: Brandy Fureman, PhD

12:40-12:45 Patient/Caregiver Perspective
Representative Iman Jodeh

12:45-1:00 Genetic Epilepsies – Etiologies or Syndromes?
Elaine Wirrell, MD

1:00-1:15 Health equity in clinical trials
Pamela S. Smith, PharmD, Pfizer

1:15-1:30 Achieving patient focused drug development – why are measure that are used, used?
James Mitchell, MD, University of Liverpool

1:30-1:45 Basket Trials
Kert Viele

1:45-2:15 Panel Discussion / Q&A

2:15-2:30 Networking Break

SESSION IX : CLINICAL DRUGS

Moderator: Jacqueline French, MD

2:30-2:40 Rozanolixizumab (inhibitor of the neonatal Fc receptor (FcRn))
Stephen Yates, UCB Biosciences, Inc.

2:40-2:50 NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:50-3:00</td>
<td>Brian Moseley, Neurocrine</td>
<td>Abi-009 surgically refractory epilepsy</td>
</tr>
<tr>
<td>3:00-3:10</td>
<td>Jason Hauptman, Seattle Children’s Hospital</td>
<td>ENX-101</td>
</tr>
<tr>
<td>3:10-3:20</td>
<td>Kimberly Vanover, Engrail</td>
<td>PRAX-562</td>
</tr>
<tr>
<td>3:20-3:30</td>
<td>Bernard Ravina, Praxis</td>
<td>Ganaxolone</td>
</tr>
<tr>
<td>3:30-3:40</td>
<td>Joseph Hulihan, Marinus Pharmaceuticals, Inc.</td>
<td>XEN1101</td>
</tr>
<tr>
<td>3:40-3:50</td>
<td>Dan Abrams, Cerebral Therapeutics</td>
<td>CT010 Valproate for ICV Administration</td>
</tr>
<tr>
<td>3:50-4:00</td>
<td>Randall Kaye, MD, CMO, Longboard Pharmaceuticals</td>
<td>LP352</td>
</tr>
<tr>
<td>4:00-4:10</td>
<td>Lilly Frohlich, Cerevel</td>
<td>Darigabat</td>
</tr>
<tr>
<td>4:10-4:20</td>
<td>Ellen Schmidt, Lundbeck</td>
<td>Focal epilepsy study in patients with RNS devices</td>
</tr>
<tr>
<td>4:20-4:30</td>
<td>Robert Roebling, UCB</td>
<td>Staccato® alprazolam</td>
</tr>
<tr>
<td>4:30-4:40</td>
<td>Pierandrea Muglia, Grin Therapeutics</td>
<td>Radiprodil</td>
</tr>
<tr>
<td>4:40-4:50</td>
<td>Mark Versavel, MD, PhD, MBA, Eliem</td>
<td>ETX-020155</td>
</tr>
<tr>
<td>4:50-5:00</td>
<td>Ellen Schmidt, Lundbeck</td>
<td>Name of Talk</td>
</tr>
<tr>
<td>5:00</td>
<td>Neurelis</td>
<td>Closing Remarks</td>
</tr>
</tbody>
</table>